UNIVEST FINANCIAL Corp Cuts Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

UNIVEST FINANCIAL Corp reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,113 shares of the medical research company’s stock after selling 63 shares during the quarter. UNIVEST FINANCIAL Corp’s holdings in Charles River Laboratories International were worth $4,046,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. VisionPoint Advisory Group LLC increased its stake in shares of Charles River Laboratories International by 105.7% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after acquiring an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter valued at about $37,000. Operose Advisors LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter valued at about $42,000. Venturi Wealth Management LLC grew its position in Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 112 shares during the last quarter. Finally, Provence Wealth Management Group purchased a new stake in Charles River Laboratories International during the 3rd quarter valued at about $57,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Up 0.4 %

NYSE:CRL traded up $1.03 during mid-day trading on Tuesday, reaching $236.30. The company’s stock had a trading volume of 472,495 shares, compared to its average volume of 543,108. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The stock has a fifty day moving average of $251.94 and a 200-day moving average of $224.81. The firm has a market capitalization of $12.17 billion, a PE ratio of 25.55, a price-to-earnings-growth ratio of 1.83 and a beta of 1.44. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. During the same period last year, the firm posted $2.98 EPS. Charles River Laboratories International’s revenue was down 7.9% on a year-over-year basis. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Analyst Ratings Changes

CRL has been the topic of several recent analyst reports. Guggenheim downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Citigroup raised their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Robert W. Baird raised their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. Finally, TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.23.

Insider Activity

In related news, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares in the company, valued at $5,685,431.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock worth $3,693,663 in the last quarter. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).